MedTrace Logo

CF And Effects of Drugs Mixed Ex Vivo With Sputum for Mucolytic Treatment

NCT01533636 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 114

Last updated 2026-02-10

No results posted yet for this study

Summary

The investigators will collect samples of sputum from healthy volunteers and patients with cystic fibrosis for the purpose of: a) purifying airway mucins for plate-based binding studies and; b) assessment of the effects of carbohydrates on the rheologic properties of the sputum.

This study has two hypotheses:

1. Lectins from Pseudomonas aeruginosa and Aspergillus fumigatus bind to airway mucins in a fucose-dependent manner, and this binding can be inhibited by fucosyl glycomimetic compounds.
2. Fucosyl glycomimetics will compete with Pseudomonas aeruginosa lectin (PA-IIL) and Aspergillus fumigatus lectin (AFL) and disrupt lectin-driven mucin cross-linking in CF sputum.

Conditions

Sponsors & Collaborators

Principal Investigators

  • John V Fahy, MD · University of California, San Francisco

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-07-17
Primary Completion
2020-03-01
Completion
2026-02-04

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01533636 on ClinicalTrials.gov